Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST	//IEMBER'S FIRST NAME:		
Instructions: Please fill outhat is important for the revontained in this form is Pr	iew (e.g., chart notes o	or lab data, to support t			
				URGENT	
MEMBER INFORMATION	١				
LAST NAME:		FIRST NAME:	FIRST NAME:		
PHONE NUMBER:		DATE OF BIRT	DATE OF BIRTH:		
STREET ADDRESS:					
CITY:		STATE:	ZIP CODE:		
PATIENT INSURANCE II	NUMBER:	1			
☐ MALE ☐ FEMALE H	HEIGHT (IN/CM):	WEIGHT (LB/KG)	: ALLERGIES: _		
IF YOU ARE NOT THE PADISCLOSURE AUTHORIZE FOLLOWING LINK: PRIM	ATION FORM WITH TETHERAPEUTICS.CO	THIS REQUEST WHIC M/NOPP (IF APPLICABLE):	H CAN BE FOUND AT TH		
AUTHORIZED REPRESEI	NTATIVE'S PHONE N	UMBER:			
PRESCRIBER INFORMA	TION				
LAST NAME:		FIRST NAME:	FIRST NAME:		
PRESCRIBER SPECIAL	гү:	EMAIL ADDRE	EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER	DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER	FAX NUMBER:		
STREET ADDRESS:					
CITY:		STATE:	STATE: ZIP CODE:		
REQUESTER (if different than prescriber):		OFFICE CONT	OFFICE CONTACT PERSON:		
MEDICATION OR MEDIC	CAL DISPENSING INF	ORMATION			
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REI	QUANTITY:		
☐ NEW THERAPY	—	IF RENEWAL: DATE			
DURATION OF THERAP	Y (SPECIFIC DATES):				
Continued on next page					

© 2017–2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 5.15.25 CAT009



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST N	IAME:			
1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?					
YES (if yes, complete below)					
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
☐ Type II diabetes ☐ Type II diabetes with establish ☐ Type II diabetes with Congest ☐ Chronic kidney disease					
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.					
Is patient going to be using drug	in combination with a clinical trial	? ☐ Yes ☐ No			
For patients with Type II diabetes	s, please answer the following:				
Is the patient's estimated glomerular filtration rate (eGFR) below 20 mL/min/1.73 m2? □ Yes □ No Please provide documentation.					
Is the patient's most recent (pre-Synjardy) HgbA1C obtained in the past 6 months 7% or greater prior to therapy (HbA1c must be taken within the past 6 months if the patient has not been on this treatment previously)? □ Yes □ No *Please provide documentation					
Is the patient currently on metformin?* □ Yes □ No					
Does the patient had an inadequate response or intolerance to metform? Yes No *Provide documentation					
Is the patient on dialysis? □ Yes □ No					
For patients with Type II diabetes following:	s with established cardiovascular d	lisease, please answer the			
Please check at least one of the f MI or Stroke Imaging shows single-vessel or Previous coronary revasculari Positive cardiac stress test Hospital admission for unstab	or multi-vessel coronary artery dise zation procedure	ease			

© 2017–2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 5.15.25 CAT009



amputation due

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	_ MEMBER'S FIRST NAME:		
to circulatory insufficiency, imaging or non- stenosis in an artery, and/or ankle: brachial index equaling	invasive study showing evidence of more than 50% less than 0.9 in an ankle.)		
For diagnosis of Type II diabetes with congesti Does patient have an ejection fraction (EF) equi documentation.	ve heart failure, please answer the following: aling 49% or less? □ Yes □ No <i>Please provide</i>		
Does patient have an ejection fraction (EF) great	ater than 49%? Please provide documentation.		
Has patient ever had NYHA class II, III or IV syndocumentation.	nptoms of heart failure? Yes No Please provide		
Does patient's body mass index (BMI) equal les documentation.	ss than 45 kg/m²? □ Yes □ No <i>Please provide</i>		
Does patient have a NT-proBNP greater than 30 documentation.	00 pg/ml? □ Yes □ No <i>Please provide</i>		
For patients with A-fib, is the NT-proBNP great documentation.	er than 900 pg/ml? □ Yes □ No <i>Please provide</i>		
IF NT-proBNP not available, does patient have Please submit chart documentation.	a BNP >100 pg/ml without kidney failure? ☐ Yes ☐ No		
If NT-proBNP not available and patient has kids Yes □ No Please submit chart documentation.	ney failure, does patient have a BNP > 200 pg/ml? □		
If NT-proBNP not available and patient has Atrial fibrillation(AF), does patient have a BNP > 150 pg/ml? □ Yes □ No Please submit chart documentation			
Please provide documentation from echocardic □ LA width >4.0cm □ LA length >5.0 cm □ LA area >20cm2 □ LA volume >55ml □ LA volume index >34ml/m2	ny defined by at least one of the following:? □ Yes □ ogram. >1.1 cm		



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	_ MEMBER'S FIRST NAME:			
Has patient been hospitalized in the past 12 mo Synjardy(empagliflozin/metformin)? □ Yes □ No Please provide documentation.	onths before starting			
Is patient on a stable dose of a diuretic? □ Yes	□ No Please provide documentation.			
Has patient had a myocardial infarction, coronary bypass graft surgery or other major cardiovascular surgery, stroke or TIA in the past 90 days of starting Jardiance? □ Yes □ No Please provide documentation.				
Has patient had a heart translplant? □ Yes □ N	lo			
Does patient have acute decompensated heart	failure? □ Yes □ No			
Does patient have severe <u>pulmonary disease</u> including severe COPD, requiring home oxygen therapy for their COPD, chronic nebulizer therapy or chronic oral steroid therapy for treatment of their severe COPD? □ Yes □ No <i>Please submit chart documentation.</i>				
Does patient have severe <u>pulmonary disease</u> including primary pulmonary hypertension? □ Yes □ No <i>Plea</i> se s <i>ubmit chart documentation.</i>				
Does patient have any other condition or diagnosis causing patient's heart failure symptoms such as patient has significant mitral valve regurgitation causing the heart failure, any dilated cardiomyopathy, infiltrative cardiomyopathy, or viral myocarditis? Yes No Please submit chart documentation.				
Does patient have and eGFR less than 20 ml/m	in/1.73 m²? □ Yes □ No			
Does patient require dialysis? □ Yes □ No				
the following: infiltrative disease accumulation disease muscular dystrophy hypertrophic obstructive cardiomyopathy known pericardial restriction valvular disease expected to lead to surgery atrial fib/flutter with a resting heart rate great	er than 110 bpm			
and renorming.				
Has patient had chronic kidney disease for 3 o documentation.	r more months? □ Yes □ No * <i>Please provide</i>			
Does patient have Type II diabetes? □ Yes □ No				



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		-IRST NAME:		
	OFD(OFD) (1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	00 45 1/ : /4 70 2 // 1 : \0		
Yes □ No *Please provide documents		ween 20 - 45ml/min/1.73m² (inclusive)? □		
Does patient have and estimated GFR(eGFR) greater than or equal to 45 to less than or equal to 9045ml/min/1.73m² with urinary albumin:creatinine ratio greater than or equal to 200mg/G or protein:creatinine ratio greater than or equal to 300mg/G? Yes No *Please provide documentation				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
Please note: Not all drugs/diagnosi required information is received.	is are covered on all plans. Th	nis request may be denied unless all		
		curate to the best of my knowledge. I		
		signees may perform a routine audit and of the information reported on this form.		
Prescriber Signature or Electroni	c I.D. Verification:	Date:		
		s transmission contain confidential health		
		ecipient, you are hereby notified that any econtents of these documents is strictly		
		notify the sender immediately (via return		
FAX) and arrange for the return or destruction of these documents.				

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP-4201

P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

